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ABSTRACT
Background: Multidisciplinary team meetings are
standard care for cancer in the UK and Europe.
Professional bodies recommend that mesothelioma
cases should be discussed at specialist
multidisciplinary team meetings. However, no evidence
exists exploring the role of the specialist mesothelioma
multidisciplinary team meeting.
Objectives: To evaluate the clinical activity of 1
specialist mesothelioma multidisciplinary team meeting
and to determine how often a definitive diagnosis was
made, whether the core requirements of the meeting
were met and whether there was any associated benefit
or detriment.
Design and setting: A service evaluation using
routinely collected data from 1 specialist mesothelioma
multidisciplinary team meeting in a tertiary referral
hospital in the South-West of England.
Participants: All cases discussed between 1/1/2014
and 31/12/2015.
Outcome measures: The primary outcome measure
was whether a definitive diagnosis was made.
Secondary outcomes included whether treatment
advice was offered, information on clinical trials
provided or further investigations suggested. Additional
benefits of the multidisciplinary team meeting and time
taken from referral to outcome were also collected.
Results: A definitive diagnosis was reached in 171 of
210 cases discussed (81%). Mesothelioma was
diagnosed in 153/210 (73%). Treatment advice was
provided for 127 of 171 diagnostic cases (74%) and
further investigations suggested for all 35 non-
diagnostic cases. 86/210 cases (41%) were invited to
participate in a trial, of whom 43/86 (50%)
subsequently enrolled. Additional benefits included the
avoidance of postmortem examination if the coroner
was satisfied with the multidisciplinary team decision.
The overall process from referral to outcome dispatch
was <2 weeks in 75% of cases.
Conclusions: This specialist mesothelioma
multidisciplinary team meeting was effective at making
diagnoses and providing recommendations for further
investigations or treatment. The core requirements of a
specialist mesothelioma multidisciplinary team meeting
were met. The process was timely, with most
outcomes returned within 2 weeks of referral.
INTRODUCTION
Mesothelioma is an aggressive cancer that
predominantly affects the pleural surface. It
is incurable, and the only effective chemo-
therapy regimen offers a median survival
beneﬁt of just 2.8 months.1 Median survival
is less than a year from diagnosis, and conse-
quently care planning needs to be timely as
well as effective.2
The multidisciplinary team (MDT) is
deﬁned by the UK Department of Health as
a group of specialists from different health-
care disciplines who meet to discuss a given
patient and determine diagnostic and treat-
ment decisions.3 MDT meetings have been
part of routine cancer care in the UK since
the publication of the National Health
Service (NHS) Cancer Plan in 2000.4 This sti-
pulated that all patients with cancer should
be discussed in cancer-speciﬁc MDT meet-
ings.4 European recommendations followed,
leading to the introduction of MDT meetings
throughout the continent.5
Since their widespread adoption as part of
the cancer pathway, MDT meetings have
been associated with enhanced patient satis-
faction,6 increased uptake of chemotherapy7
and increased recruitment to clinical
Strengths and limitations of this study
▪ This is the first study to describe the role of the
specialist mesothelioma multidisciplinary team
meeting.
▪ The study uses data collected on all cases from
one tertiary referral centre over a 2-year period.
▪ This study will inform the forthcoming British
Thoracic Society Mesothelioma Guidelines.
▪ This is a single-centre study, so results may not
be generalisable.
▪ Dispatch date for multidisciplinary team meeting
outcome was missing in 30% of cases, poten-
tially introducing bias.
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trials.8 9 Some studies have reported improved survival
outcomes following the implementation of MDT meet-
ings, in particular, in oesophageal, lung, ovarian and
breast cancer.10–13 However, these observational studies
may have been affected by confounding factors, such as
concurrent advances in diagnostics or treatment. A sys-
tematic review concluded that MDT meetings can inﬂu-
ence clinical decision-making, but there is insufﬁcient
evidence regarding their effect on outcomes.14
Consideration must also be given to the potential pitfalls
of MDT meetings, including the resources needed to
run the meeting and the potential ramiﬁcations of indi-
vidual clinicians not following MDT advice.
The UK Department of Health’s 2007 Mesothelioma
Service Framework advised that specialist mesothelioma
MDT meetings should be held to discuss cases of diag-
nostic difﬁculty where mesothelioma is suspected.15 The
2007 British Thoracic Society (BTS) Mesothelioma
Statement endorsed this, recommending that challen-
ging cases be referred to a specialist mesothelioma MDT
meeting.16 Additionally, patients with good performance
status should be discussed at mesothelioma MDT meet-
ings to determine appropriate management plans and
screen for clinical trial participation.15 16
According to the 2007 Mesothelioma Service
Framework,15 the core requirements of the mesotheli-
oma MDT meeting are:
▸ To review the pathological and radiological evidence
for the diagnosis;
▸ To make recommendations regarding chemotherapy;
▸ To encourage the recruitment of appropriate patients
to clinical trials.
The BTS is currently writing new guidelines for meso-
thelioma. Publication is expected in late 2016, and they
are likely to encourage the involvement of specialist
mesothelioma MDT meetings. However, the worldwide
literature currently contains no research either describ-
ing the role of the specialist mesothelioma MDT meeting
or evaluating its potential beneﬁts or disadvantages.
The aim of this study was to describe the clinical acti-
vity of one specialist mesothelioma MDT meeting, and
to determine how effective it was in terms of achieving a
deﬁnitive diagnosis. Secondary aims were to review
whether the Mesothelioma Service Framework core
requirements were met, and to assess whether the meso-
thelioma MDT meeting was associated with any add-
itional beneﬁt or detriment. Of speciﬁc interest was the
time taken for the MDT meeting process, as delays
could impact on treatment.
METHODS
This was a service evaluation of one specialist mesotheli-
oma MDT meeting over a 2-year period.
Setting
One specialist mesothelioma MDT meeting in the
South-West of England, covering one cancer network
with a geographical area of 2500 square miles and a
population of 2.4 million. The mesothelioma MDT
meeting is held once a week, for 30 min to 1 hour. The
MDT meeting is attended by a respiratory physician with
a special interest in pleural disease, a thoracic oncolo-
gist, a respiratory radiologist and a histopathologist who
specialises in pleural disease. In addition, a thoracic
surgeon is in attendance at ∼20% of meetings.
Identification of cases
All cases discussed at the mesothelioma MDT meeting
between 1/1/2014 and 31/12/2015 were included.
Cases were identiﬁed from mesothelioma MDT meeting
lists recorded prospectively on the Network Cancer
Database. Cases were also identiﬁed from a local archive
of mesothelioma MDT meeting outcomes recorded at
the time of discussion, and a separate prospectively col-
lected mesothelioma database (part of the ‘Investigating
Pleural Disease Study’, UKCRN 8960, REC reference
number 08/H0102/11). A case was deﬁned as a single
discussion at the mesothelioma MDT meeting, occurring
on one occasion. Patients discussed on more than one
occasion were treated as separate cases for each discus-
sion episode.
Data collection
Data were collected from completed MDT meeting pro-
formas, obtained from electronic archives for all
patients. An example of the proforma is shown in online
supplementary appendix A and the full data extraction
strategy demonstrated in online supplementary appen-
dix B.
The referral section of the proforma was completed
by clinicians at the referring hospital and emailed or
faxed to the mesothelioma MDT meeting coordinator
prior to the meeting. This section contained patient
information and outlined the advice requested from the
MDT meeting. Patient demographics, data on the refer-
ring hospital and any diagnoses already made by the
local MDT meeting were obtained from the referral
section of the proforma.
The outcome section of the proforma was completed
by the respiratory physician in attendance at the meso-
thelioma MDT meeting, at the time of case discussion.
The clinical information discussed, the diagnosis made
by the mesothelioma MDT, recommendations for treat-
ment and advice about clinical trials were recorded in
this section of the proforma.
Free-text advice was sometimes written in the outcome
section of the proforma. If this advice did not relate to
the prespeciﬁed outcome measures, it was deﬁned as
‘additional beneﬁt provided by the MDT meeting’ and
described narratively. One additional beneﬁt that was
revealed during the study period was the potential to
avoid a postmortem if a diagnosis of mesothelioma was
conﬁrmed by the mesothelioma MDT meeting. Since
this was not consistently recorded, and because not all
the patients discussed during the study period had died,
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the coroner’s ofﬁce was contacted to enquire how many
patients had beneﬁtted from this.
Prior to November 2014, proforma use was not univer-
sal. Data for patients discussed prior to this date were
extracted from the MDT meeting referral letter and
MDT meeting outcome letter, obtained from local hos-
pital records. Following the introduction of the MDT
meeting proforma in November 2014, referral letters
and outcome letters were rarely used, but where they
were available, they were obtained and used for data
extraction alongside the proforma.
MDT outcomes for all cases were cross-referenced with
summary reports recorded by the MDT coordinator
onto the National Cancer Database at the time of discus-
sion at the MDT meeting.
The date of referral to and discussion at the meso-
thelioma MDT meeting were obtained from the MDT
meeting proforma, referral letters and outcome letters.
The date of dispatch of MDT meeting outcome was
obtained from outcome letters (if the electronic pro-
forma was not used) or from the electronic record of
sent emails from the MDT meeting coordinator’s email
account (for electronic proformas).
Clinical trial participation was assessed using an online
research registry of clinical trial participants, managed
and maintained by the Research and Development
department of the NHS Trust where the MDT meeting
was based.
Data extraction was undertaken by ACB and KW, with
support from SS and NB between 1/2/2016 and 26/2/
2016.
Ethics approval
Ethics approval was not necessary for this service evalu-
ation. Data were collected and stored in accordance with
local ethics committee guidance and good clinical prac-
tice guidelines.
Outcome measures
The primary outcome was whether a deﬁnitive diagnosis
was reached, and what the diagnosis was.
Secondary outcomes were whether a diagnosis repre-
sented conﬁrmation of an existing diagnosis, change of exist-
ing diagnosis to an alternate one, or formation of a new
clinicohistoradiological diagnosis. Clinicohistoradiological
diagnoses were deﬁned as cases where test results were
non-diagnostic in isolation but, when reviewed in com-
bination, were sufﬁcient to allow the specialist MDT to
make a deﬁnitive diagnosis.
For non-diagnostic cases, it was noted whether the spe-
cialist MDT meeting provided advice on subsequent
investigations.
Other secondary outcomes included assessment of
whether the 2007 Mesothelioma Service Framework
core requirements had been fulﬁlled, that is, whether
radiology and pathology were discussed, whether any
treatment recommendations were made and whether
cases were identiﬁed as eligible for clinical trials. The
time taken for the MDT process was evaluated using the
date of referral to the MDT meeting, date of discussion
at the meeting and date of dispatch of MDT meeting
outcome back to the original referrer.
Finally, any additional advice or clinical service that
was documented in the free-text section of the MDT
meeting outcome proforma was collected, and included
under the outcome ‘additional beneﬁt’. In order to
capture all potential beneﬁts, the deﬁnition of this
outcome was not prespeciﬁed, and all comments were
included.
Statistical analysis
Descriptive statistics were used. Characteristics of cases
were tabulated, as were MDT meeting outcomes and
diagnoses. Binary outcome measures were reported as
percentages. Medians and IQRs were reported for time-
based outcome measures. Statistical analysis was under-
taken by ACB, with support from NAM, using Stata V.13
(StataCorp LP, Texas, USA).
RESULTS
The mesothelioma MDT meeting discussed 210 cases
during the study period. This represented 194 patients,
of whom 179 were discussed once, 14 twice and 1 on
three occasions.
Case demographics
Table 1 shows the characteristics of all cases discussed at
the mesothelioma MDT meeting. The majority of cases
discussed at the mesothelioma MDT meeting were male
(184/210; 87.6%), with a mean age of 74 years (range
50–93 years). WHO performance status ranged from 0—
able to carry out all normal activity without restriction,
to 5—dead (see online supplementary appendix C for a
full description of WHO performance status).17
Information on performance status was missing for 36/
210 cases (17%), but otherwise there were no missing
data for case characteristics or referral information.
Primary outcome
Data were obtained for all cases. Of 210 cases, a deﬁni-
tive diagnosis was made in 171 (81%), 35 (17%) were
non-diagnostic and 4 (2%) had established mesotheli-
oma and were referred to the MDT meeting for advice
(table 2).
Of the 171 diagnostic cases, the mesothelioma MDT
meeting decision represented conﬁrmation of an exist-
ing diagnosis in 127 (74%). In 22 of 171 diagnostic cases
(13%) the original diagnosis was overturned and an
alternate diagnosis made, and in another 22/171 (13%)
a clinicohistoradiological diagnosis was made.
Mesothelioma was diagnosed in 153 of 171 diagnostic
cases (89%), of which histological subtype was con-
ﬁrmed in 134/153 (88%). In all 35 non-diagnostic cases,
subsequent investigations were advised. In the majority
of cases a repeat pleural biopsy (19/35; 54%) was
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advised, with guidance on which technique of obtaining
tissue was likely to be most beneﬁcial. In 12/35 (34%)
non-diagnostic cases an interval CT scan was
recommended.
Secondary outcomes
Data on secondary outcomes were available for all cases,
except date of dispatch of MDT meeting outcome,
which was missing in 61/210 cases (29%).
Regarding the core requirements as stated in the 2007
Mesothelioma Service Framework,15 the mesothelioma
MDT meeting reviewed both radiology and pathology in
185/210 cases (88%). Radiology alone was reviewed in
17/210 cases (8%) and pathology alone in 7/210 cases
(3%). Treatment advice was offered in 127 of 171 diag-
nostic cases (74%) and all four cases referred to the
MDT meeting for advice. Advice included palliative
chemotherapy, prophylactic/palliative radiotherapy or
both in 94/127 cases (72%) and active symptom control
in 26/127 (20%). Observation was recommended for 9/
127 cases (7%) with non-malignant diagnoses. Of 210
cases, 86 (41%) were invited to participate in a clinical
trial, of whom 43/86 (50%) subsequently enrolled.
Referral dates and MDT meeting dates were available
for all cases. The median time from referral to discus-
sion at the mesothelioma MDT meeting was 7 days (IQR
6–12 days). In total, 179/210 cases (85%) were discussed
within 14 days.
The date the MDT meeting outcome was dispatched
back to the original referrer was available in 149/210
cases (71%). For these cases, the median time from dis-
cussion at the MDT meeting to dispatch of outcome was
1 day (IQR 0–1). Outcomes were dispatched within
7 days of MDT meeting discussion in 142/149 cases
(95%). Median overall time from receipt of referral to
dispatch of MDT outcome was 8 days (IQR 7–14). The
majority of cases where dispatch date was missing (42/
61; 69%) were discussed prior to November 2014 and
the introduction of electronic MDT meeting proformas.
There was no difference in age, sex, performance status,
likelihood of achieving a deﬁnitive diagnosis or ﬁnal
diagnosis in patients with missing data for this outcome
compared with patients without missing data.
In 15/210 cases (7%), the mesothelioma MDT
meeting offered additional beneﬁt, including a second
opinion from an expert mesothelioma pathologist (6/
210; 3%), compensation advice (4/210; 2%) and a bio-
marker test not otherwise available (2/210; 1%).
Another beneﬁt of the mesothelioma MDT meeting
related to postmortems. The coroner covering part of
this geographical region agreed that in cases with
Table 2 Outcomes of the specialist mesothelioma
multidisciplinary team (MDT) meeting
MDT meeting outcome (all cases) N (%)
Diagnostic 171 (81)
Non-diagnostic 35 (17)
Diagnosis already known, referred for advice
only
4 (2)
Total 210 (100)
MDT meeting outcome (diagnostic cases only)
Confirmation of diagnosis made by local
MDT
127 (74)
Alternative diagnosis made 22 (13)
Consensus clinicohistoradiological diagnosis
made
22 (13)
Total 171 (100)
Epithelioid mesothelioma 90 (53)
Sarcomatoid mesothelioma 28 (16)
Biphasic mesothelioma 12 (7)
Desmoplastic mesothelioma 4 (2)
Peritoneal mesothelioma 5 (3)
Mesothelioma, unspecified 14 (8)
Other cancer 6 (4)
Lymphoma 1
Undifferentiated carcinoma 2
Metastatic adenocarcinoma (lung) 2
Metastatic lung cancer 1
Metastatic neck cancer 1
Non-malignant 12 (7)
Total 171 (100)
Table 1 Summary of cases discussed at the
mesothelioma multidisciplinary team (MDT) meeting
N (%)
Total MDT meeting discussions 210 (100)
Total number of patients discussed 194
Patients discussed on 1 occasion 179
Patients discussed on 2 occasions 14
Patients discussed on 3 occasions 1
Gender
Male 184 (87.6)
Female 26 (12.4)
Age (years)
Range 50–93
Mean 74
SD 7.86
WHO performance status
0 45 (21.4)
1 77 (36.7)
2 26 (12.3)
3 22 (10.5)
4 1 (0.5)
5 3 (1.4)
Not recorded 36 (17.1)
Referred by: distance
Hospital A 0 miles 75 (35.7)
Hospital B 13 miles 41 (19.5)
Hospital C 48 miles 35 (16.7)
Hospital D 3 miles 26 (12.4)
Hospital E 45 miles 12 (5.7)
Hospital F 35 miles 9 (4.3)
Hospital G 5 miles 9 (4.3)
Hospital H 38 miles 1 (0.5)
Hospital I 76 miles 1 (0.5)
Hospital J 123 miles 1 (0.5)
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conﬁrmatory pathology, a recent consultant review and
previous ratiﬁcation of the diagnosis at the specialist
MDT meeting, postmortem examination was not auto-
matically required. In the 2-year study period, this
removed the need for postmortems in 47 patients.
DISCUSSION
This is the ﬁrst formal evaluation of a specialist meso-
thelioma MDT meeting using data collected either pro-
spectively or contemporaneously to clinical practice. The
mesothelioma MDT meeting was found to be effective,
with high diagnostic rates and advice on subsequent
investigations offered in all non-diagnostic cases. The
mesothelioma MDT meeting met the core requirements
stated by the UK Department of Health’s 2007
Mesothelioma Service Framework—to review both hist-
ology and radiology, to offer advice on treatment, and to
identify potential participants for clinical trials.15 In add-
ition to this, the mesothelioma MDT meeting was asso-
ciated with further beneﬁts, notably removing the need
for postmortem examination in cases where the coroner
was satisﬁed with the clinical diagnosis. Finally, the meso-
thelioma MDT meeting was efﬁcient, with most out-
comes sent within 2 weeks of the original referral. This
is reassuring, and suggests that referral to the specialist
MDT meeting is not associated with signiﬁcant delays to
subsequent treatment or further investigations.
This study had limitations. Although clinical informa-
tion was collected either prospectively or at the time of
the mesothelioma MDT meeting, identiﬁcation of cases
was retrospective. However, use of Network Cancer
Database MDT meeting lists ensured comprehensive
case identiﬁcation. Interrogation of alternative data
sources did not reveal additional cases, suggesting case
identiﬁcation was robust.
Dispatch dates were missing in one-third of cases, the
majority of which were discussed prior to November
2014. The MDT meeting outcome system changed in
November 2014 from typed posted letters to emailed pro-
formas. The latter process left a clearer audit trail and
hence fewer missing data. However, the electronic system
is likely to have resulted in swifter dispatch of outcomes
than the previous paper-based system, and therefore bias
may have been introduced. Consequently the timings
reported in this study should be seen as a reﬂection of an
electronic referral and response system, as for the major-
ity of cases included in the analysis, this was the case.
It is a strength of this study that, apart from dispatch
date of MDT meeting outcome and information on
patient performance status, there was no missing data.
This is likely to be a result of using multiple sources to
collect data, and cross-referencing all cases with the
National Cancer Database. This also helped remove
potential bias from the study, as different data sources
were completed by different members of the MDT team
(eg, MDT outcome proforma was completed by the
respiratory clinician, while data were entered onto the
National Cancer Database by the MDT coordinator).
There was no conﬂict between the data extracted from
these different sources.
This study reports data from one specialist mesotheli-
oma MDT meeting. It may not be representative of other
mesothelioma MDT meetings, and the generalisability of
the results is unknown. While diagnostic success rates
should not vary greatly between MDT meetings, other
outcomes may differ depending on the frequency of
meetings and amount of research activity at each centre.
Further studies are needed to determine the efﬁcacy of
specialist mesothelioma MDT meetings as a whole.
Similarly, cases of mesothelioma not referred to the
regional mesothelioma MDT meeting were not included
in this study. Future research could investigate what pro-
portion of mesothelioma cases are referred to the MDT
meeting and whether there is a relationship between
patient outcomes and discussion at the specialist MDT
meeting. Comparing the characteristics and outcomes of
patients who are discussed at the mesothelioma MDT
meeting with those who are not would be the ﬁrst step
in exploring this area.
This study did not evaluate the role of allied health
professionals in the mesothelioma MDT meeting. Future
research could focus on the involvement of mesotheli-
oma clinical nurse specialists, referral to palliative care
services and whether patient support groups were
recommended. A multicentre, randomised trial is cur-
rently underway in the UK assessing the impact of early
palliative care input on patient-reported, health-related
quality of life in mesothelioma.18 The outcome of this
trial could potentially change practice in mesothelioma,
and encourage the involvement of mesothelioma spe-
cialist nurses and palliative care physicians in mesotheli-
oma MDT meetings.
This study did not assess survival outcomes or patient
satisfaction scores in relation to the mesothelioma MDT
meeting. Consequently these results cannot be com-
pared with existing research looking at these out-
comes.6 10–13 This is another area of interest for future
research projects.
MDT meetings are part of routine cancer care in the
UK, and it would not be possible or ethical to undertake
a randomised controlled trial assessing their value.
However, in order to maintain and improve standards of
care for patients with mesothelioma, specialist MDT
meetings should be regularly audited. The development
of national standards may be of beneﬁt.
CONCLUSION
Discussion of mesothelioma cases at this specialist MDT
meeting provided the opportunity to review diagnoses,
offer advice on investigations and treatment, and
encourage recruitment to clinical trials. Evaluation of
the service at this single-centre MDT meeting suggests
specialist mesothelioma MDT meetings can add value to
patient care, without introducing signiﬁcant time delays.
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